查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844139

藥物遞送和基因遞送裝置市場（按技術、裝置類型、分子類型、最終用戶、應用和治療領域分類）－2025-2032年全球預測

Drug & Gene Delivery Devices Market by Technology, Device Type, Molecule Type, End User, Application, Therapeutic Area - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物輸送和基因輸送設備市場將成長至 110.6 億美元，複合年成長率為 11.03%。

主要市場統計數據
基準年 2024 47.9億美元
預計年份：2025年 53.2億美元
預測年份：2032年 110.6億美元
複合年成長率 (%) 11.03%

對藥物遞送和基因遞送裝置領域進行策略性介紹，重點關注材料創新、數位化系統、不斷變化的監管環境以及患者需求。

現代藥物遞送和基因遞送裝置的格局是由材料創新、數位化以及對患者療效的持續關注三者融合而成。生物材料的最新進展，結合微型電子元件和整合感測器，為精準給藥、封閉式遞送和遠端監測創造了新的機會。同時，監管預期和報銷框架也在不斷發展，以適應組合藥物和數位化擴展療法，這要求裝置開發人員從一開始就將臨床、技術和商業性因素整合起來。

本部分探討了科學創新與實際應用之間的相互作用。它重點闡述了多學科團隊的重要性，這些團隊匯集了聚合物科學家、配方專家、機械工程師、軟體工程師和臨床相關人員，共同開發差異化的給藥方案。此外，本部分也指出，病患體驗作為設計促進因素的作用日益凸顯，易用性、安全性和依從性如今直接影響藥物的採納。最後，本部分透過闡明決定未來幾年哪些技術和經營模式能夠成功的關鍵因素，為後續的詳細分析奠定了基礎。

材料突破、數位化工具、製造創新和監管動態正在發生變革性轉變，再形成藥物傳輸和基因輸送裝置。

變革性的轉變正在重塑藥物和基因傳遞裝置的競爭格局和技術格局。材料科學的突破，例如先進水凝膠、脂質奈米顆粒系統和多功能聚合物，正在催生新的製劑和控制釋放方案。同時，數位化工具和嵌入式感測器正在將裝置從被動載體轉變為智慧平台，為臨床醫生和支付方提供劑量智慧、依從性回饋和真實世界資料流。

模組化、可擴展生產方式和本土化能力的投資正在縮短複雜交付系統的前置作業時間並提升品管。監理預期也在同步變化，監理機關更重視綜合風險管理、連網型設備的網路安全以及生命週期資料。總而言之，這些轉變有利於那些將深厚的材料專業知識與系統工程、可靠的臨床證據產生以及靈活的監管策略相結合的企業。因此，多學科融合而非單一技術優勢將決定永續的差異化優勢。

評估2025年美國關稅對供應鏈、零件採購、定價策略和製造業韌性的累積影響

美國宣布並實施的關稅政策將持續到2025年，將對藥物輸送和基因輸送設備生態系統產生多方面的影響。關稅將改變零件採購的經濟格局，使一些進口材料和次組件價格上漲，並促使企業尋求替代籌資策略。這項變更將迫使製造商和設備開發商重新評估其供應商組合，考慮更近的採購方案，並加快二級供應商的資格認證，以降低單一來源風險。

除了直接的成本影響外，關稅還會影響企業在製造和最終組裝方面的策略決策。擁有靈活模組化製造架構的企業更有能力調整生產佈局，以應對投入成本的波動。採購團隊需要重新調整整體擁有成本模型，將關稅、物流波動和前置作業時間延長等因素的影響納入考量。重要的是，在採購模式轉變的過程中，也必須預先考慮監理申報和供應商變更管理等問題。最終結果是，供應鏈韌性和本地化能力建設將再次成為設備製造商及其合作夥伴的核心策略重點。

透過細分市場分析，深入了解技術選擇、設備類型、分子類別、最終用戶、應用和治療重點如何影響設計和採用。

嚴謹的細分方法揭示了不同技術平台、器械形式、分子類別、治療環境、應用目標和治療重點在設計選擇和商業化路徑上的差異。技術研究著重於水凝膠、脂質體、奈米顆粒和聚合物基平台，每種平台都具有獨特的釋放動力學、穩定性特徵以及對敏感生技藥品和基因療法的兼容性考慮。這些材料選擇直接影響器械結構、無菌策略和低溫運輸要求。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用穿戴式電化學感測器最佳化胰島素持續給藥
  • 用於靶向體內基因編輯的基於 CRISPR 的新型脂質奈米顆粒製劑
  • 將人工智慧預測模型整合到智慧輸液幫浦中，用於個人化腫瘤治療
  • 開發用於局部化療傳遞的超音波觸發微氣泡載體
  • 用於持續釋放肽類藥物的可生物分解聚合物植入的研究進展
  • 利用自擴增mRNA脂質奈米顆粒增強免疫療法
  • 可擴展基因治療載體生產的品質源自於設計方法的監管協調

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 按技術分類的藥物傳輸和基因傳輸設備市場

  • 水凝膠基
  • 脂質體
  • 奈米顆粒
  • 聚合物基

9. 按設備類型分類的藥物傳輸和基因傳輸設備市場

  • 自動噴油器
  • 點滴幫浦
  • 無針注射器
  • 筆式注射器
  • 注射器

10. 依分子類型分類的藥物遞送和基因遞送裝置市場

  • 生技藥品
    • 單株抗體
    • 胜肽
    • 重組蛋白
  • 基因治療
    • 非病毒性
      • 基於脂質的
      • 聚合物基
    • 病毒載體
      • 腺病毒
      • 慢病毒
      • 逆轉錄病毒
  • 小分子

11. 按最終用戶分類的藥物傳輸和基因傳輸設備市場

  • 診所
  • 家庭醫療保健
  • 醫院
  • 實驗室

12. 按應用分類的藥物傳輸和基因傳輸設備市場

  • 控釋
  • 智慧配送
  • 緩釋
  • 定向投放

13. 按治療領域分類的藥物傳遞和基因傳遞設備市場

  • 心血管系統
  • 糖尿病
  • 感染疾病
  • 腫瘤學

14. 各地區藥物傳輸及基因傳遞設備市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 按組別分類的藥物傳輸和基因傳輸設備市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國藥物傳輸與基因傳遞設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Becton Dickinson and Company
    • West Pharmaceutical Services, Inc.
    • Terumo Corporation
    • Gerresheimer AG
    • Baxter International Inc.
    • Nipro Corporation
    • Stevanato Group SpA
    • SHL Medical AG
    • Ypsomed Holding AG
    • Lonza Group AG
Product Code: MRR-A86604082727

The Drug & Gene Delivery Devices Market is projected to grow by USD 11.06 billion at a CAGR of 11.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.79 billion
Estimated Year [2025] USD 5.32 billion
Forecast Year [2032] USD 11.06 billion
CAGR (%) 11.03%

Strategic introduction to the drug and gene delivery device landscape highlighting materials innovation, digital systems, regulatory change, and patient needs

The modern drug and gene delivery device landscape is defined by a convergence of materials innovation, digital enablement, and a relentless focus on patient outcomes. Recent advances in biomaterials, coupled with miniaturized electronics and embedded sensors, have created new opportunities for precision dosing, closed-loop delivery, and remote monitoring. At the same time, regulatory expectations and reimbursement frameworks are evolving to account for combination products and digitally augmented therapeutics, requiring device developers to integrate clinical, technical, and commercial considerations from the outset.

This introduction frames the interplay between scientific innovation and practical deployment. It highlights how cross-disciplinary teams-bringing together polymer scientists, formulation experts, mechanical and software engineers, and clinical stakeholders-are now required to develop differentiated delivery solutions. The narrative also recognizes the growing role of patient experience as a design driver: ease of use, safety, and adherence now directly influence adoption. Finally, the section sets a foundation for the deeper analyses that follow, establishing the critical dependencies that will determine which technologies and business models succeed in the coming years.

Transformative shifts reshaping drug and gene delivery devices through materials breakthroughs, digital tools, manufacturing innovation, and regulatory dynamics

Transformative shifts are reshaping the competitive and technical landscape for drug and gene delivery devices. Materials science breakthroughs such as advanced hydrogels, lipid nanoparticle systems, and multifunctional polymers are enabling new formulations and controlled-release profiles. Concurrently, digital tools and embedded sensors are transitioning devices from passive carriers to intelligent platforms that provide dosing intelligence, adherence feedback, and real-world data streams for clinicians and payers.

Manufacturing innovation is another vector of change: modular, scalable production approaches and investments in onshore capabilities are reducing lead times and improving quality control for complex delivery systems. Regulatory expectations are moving in parallel, with authorities placing greater emphasis on integrated risk management, cybersecurity for connected devices, and lifecycle data. Taken together, these shifts favor organizations that combine deep materials expertise with systems engineering, robust clinical evidence generation, and nimble regulatory strategies. The result is a landscape where multidisciplinary integration, rather than single-technology advantage, determines sustainable differentiation.

Assessing cumulative effects of United States tariffs for 2025 on supply chains, component sourcing, pricing strategies, and manufacturing resilience

The announcement and implementation of United States tariffs for 2025 introduces a multi-dimensional effect on the drug and gene delivery device ecosystem. Tariffs alter the economics of component sourcing, making some imported materials and subassemblies more expensive and incentivizing alternative sourcing strategies. This change forces manufacturers and device developers to re-evaluate supplier portfolios, consider nearer-shore options, and accelerate qualification of secondary suppliers to mitigate single-source risk.

Beyond immediate cost implications, tariffs can influence strategic decisions about where to locate manufacturing and final assembly. Firms with flexible, modular manufacturing architectures are better positioned to shift production footprints and absorb input-cost variability. Procurement teams will need to rework total-cost-of-ownership models to incorporate tariff impacts, logistics volatility, and longer lead times. Importantly, regulatory submissions and supplier change controls must be anticipated as part of these sourcing shifts. The net effect is a renewed emphasis on supply chain resilience and localized capability development as core strategic priorities for device makers and their partners.

Segmentation insights on how technology selection, device types, molecule classes, end users, applications, and therapeutic focus shape design and adoption

A disciplined segmentation approach reveals where design choices and commercialization pathways diverge across technology platforms, device formats, molecular classes, care settings, application goals, and therapeutic priorities. Based on Technology, studies focus on Hydrogel Based, Liposomal, Nanoparticle, and Polymer Based platforms, each offering distinct release kinetics, stability profiles, and compatibility considerations for sensitive biologics and gene therapies. These material choices directly shape device architecture, sterility strategies, and cold-chain requirements.

Based on Device Type, analysis spans Auto Injector, Infusion Pump, Needle Free Injector, Pen Injector, and Syringe formats; device ergonomics, actuation mechanisms, and safety interlocks vary significantly across these forms and create different barriers to entry. Based on Molecule Type, the landscape distinguishes Biologic, Gene Therapy, and Small Molecule programs. The Biologic category further breaks into Monoclonal Antibody, Peptide, and Recombinant Protein, each with unique handling and delivery constraints. The Gene Therapy segment is split between Non Viral and Viral Vector approaches, where Non Viral divides into Lipid Based and Polymer Based carriers and Viral Vector workstreams include Adenoviral, Lentiviral, and Retroviral vectors-factors that influence manufacturing complexity, regulatory pathways, and cold-chain logistics.

Based on End User, insights cover Clinics, Home Healthcare, Hospitals, and Research Laboratories, highlighting different training, support, and device maintenance requirements. Based on Application, analysis evaluates Controlled Release, Smart Delivery, Sustained Release, and Targeted Delivery objectives and how they map to therapeutic intent. Based on Therapeutic Area, the review emphasizes Cardiovascular, Diabetes, Infectious Diseases, and Oncology, each bringing distinct clinical endpoints, dosing windows, and payer dynamics that shape product design and evidence strategies. Together, these segmentation dimensions create an analytical scaffolding for prioritizing investments and tailoring commercialization approaches to specific clinical and market realities.

Regional view of adoption, regulatory climate, manufacturing capabilities, and commercialization across Americas, Europe, Middle East & Africa, Asia-Pacific

Regional dynamics exert a profound influence on adoption timing, regulatory approach, manufacturing strategy, and commercialization pathway. In the Americas, there is a strong emphasis on rapid commercialization, large-scale clinical validation, and integrated care pathways that support device-enabled therapeutics; market entrants often prioritize scalable manufacturing and robust post-market surveillance. In Europe, Middle East & Africa, regulatory heterogeneity and national reimbursement systems require tailored market access strategies, localized clinical evidence, and partnerships with regional distributors to navigate fragmented procurement environments.

In Asia-Pacific, growth is frequently driven by a mix of local innovation hubs, cost-sensitive manufacturing, and rapidly expanding home-health adoption, all of which favor cost-effective, user-friendly devices that can be deployed at scale. Across these regions, differences in supply chain resilience, talent availability, and standards for clinical data shape where companies choose to invest in production capacity, R&D, and commercial teams. Companies that align regulatory strategy, manufacturing footprint, and commercialization priorities with these regional nuances can accelerate market entry and reduce unforeseen compliance or logistics risks.

Company-level insights on strategic alliances, technology portfolios, manufacturing investments, regulatory positioning, and competitive differentiation

Company-level strategies are increasingly centered on ecosystem plays that combine proprietary technologies with strategic partnerships. Leaders invest selectively in platform technologies that can be adapted across multiple device types and therapeutic areas, while also building alliances with contract manufacturers, formulation specialists, and digital health vendors. These collaborations reduce time-to-market for complex combination products and distribute technical risk across a broader partner network.

Investment decisions hinge on demonstrable differentiation: robust IP in delivery mechanisms, validated compatibility with high-value molecules such as monoclonal antibodies or viral vectors, and a credible path to regulatory approval. Firms that disclose clear manufacturing roadmaps, including plans for scale-up and quality systems alignment, tend to attract more favorable partnerships and procurement opportunities. Equally important is a company's ability to generate clinician and patient-centric evidence demonstrating improved adherence, reduced complications, or streamlined care pathways. This evidence underpins discussions with payers and health systems and becomes a decisive factor in adoption and reimbursement conversations.

Practical recommendations for industry leaders to prioritize technologies, refine device design, fortify supply chains, and elevate patient care strategies

Industry leaders should take decisive actions to convert insight into competitive advantage. Prioritize investments in platform technologies that demonstrate cross-therapeutic applicability and compatibility with sensitive biologics and gene vectors, and allocate R&D resources to integrate digital functions that measurably improve adherence and clinical outcomes. Strengthen supplier relationships by qualifying multiple sources for critical components and by developing nearer-shore or dual-source strategies to reduce exposure to global tariff and logistics disruptions.

Refine device design by centering human factors and real-world use cases early in development to ensure high usability across Clinics, Home Healthcare, and Hospitals. Align regulatory strategy with evidence-generation plans that can support combination product submissions and address cybersecurity expectations for connected devices. Finally, embed commercialization thinking into product development so that clinical evidence, pricing models, and distribution approaches evolve in parallel with technical milestones; this reduces go-to-market friction and accelerates payer and provider conversations.

Research methodology outlining data sources, primary and secondary research steps, validation protocols, and analytical frameworks applied to device assessment

The research methodology integrates primary interviews, targeted technical validation, and secondary research to build a robust evidence base. Primary research includes structured interviews with executives, R&D leaders, regulatory specialists, manufacturing partners, and clinicians to capture real-world constraints, adoption drivers, and unmet needs. Secondary research encompasses peer-reviewed literature, regulatory guidance documents, patent filings, and corporate disclosures to triangulate technical capabilities and historical precedent.

Validation protocols involve cross-checking interview findings against public filings and regulatory submissions, while analytical frameworks combine technology readiness assessments, supply chain risk scoring, and adoption-mapping exercises. Data synthesis emphasizes reproducibility and auditability: assumptions are documented, sensitivity analyses are conducted where appropriate, and methodological limitations are clearly stated. This layered approach ensures that conclusions rest on multiple evidence streams and that recommendations are actionable for R&D, regulatory, and commercial stakeholders.

Concluding synthesis highlighting strategic priorities, technology trends, regulatory context, and the need to align device design with patient and market realities

The conclusion synthesizes the strategic imperatives uncovered across materials platforms, device modalities, supply chain realities, and regional dynamics. It emphasizes that success in the drug and gene delivery device space requires integrated thinking: technical differentiation must be coupled with manufacturing scalability, regulatory foresight, and commercialization readiness. Stakeholders that coordinate these elements early in the product lifecycle are better positioned to navigate approval pathways, secure favorable procurement, and demonstrate real-world value to clinicians and payers.

Looking ahead, the most sustainable advantages will accrue to organizations that can combine platform extensibility with evidence-generation frameworks that speak to both clinical outcomes and total cost of care. Companies should view device development not as a one-off engineering challenge but as an end-to-end program that links scientific innovation to patient experience and market access. This alignment is the core determinant of long-term adoption and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of wearable electrochemical sensors for continuous insulin dosing optimization
  • 5.2. Emergence of CRISPR-based lipid nanoparticle formulations for targeted in vivo gene editing
  • 5.3. Integration of AI predictive models in smart infusion pumps for personalized oncology therapies
  • 5.4. Development of ultrasound-triggered microbubble carriers for localized chemotherapeutic delivery
  • 5.5. Advancements in biodegradable polymeric implants for sustained release of peptide therapeutics
  • 5.6. Use of self-amplifying mRNA lipid nanoparticles for enhanced immunotherapy applications
  • 5.7. Regulatory alignment on quality-by-design approaches for scalable gene therapy vector manufacturing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug & Gene Delivery Devices Market, by Technology

  • 8.1. Hydrogel Based
  • 8.2. Liposomal
  • 8.3. Nanoparticle
  • 8.4. Polymer Based

9. Drug & Gene Delivery Devices Market, by Device Type

  • 9.1. Auto Injector
  • 9.2. Infusion Pump
  • 9.3. Needle Free Injector
  • 9.4. Pen Injector
  • 9.5. Syringe

10. Drug & Gene Delivery Devices Market, by Molecule Type

  • 10.1. Biologic
    • 10.1.1. Monoclonal Antibody
    • 10.1.2. Peptide
    • 10.1.3. Recombinant Protein
  • 10.2. Gene Therapy
    • 10.2.1. Non Viral
      • 10.2.1.1. Lipid Based
      • 10.2.1.2. Polymer Based
    • 10.2.2. Viral Vector
      • 10.2.2.1. Adenoviral
      • 10.2.2.2. Lentiviral
      • 10.2.2.3. Retroviral
  • 10.3. Small Molecule

11. Drug & Gene Delivery Devices Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Research Laboratories

12. Drug & Gene Delivery Devices Market, by Application

  • 12.1. Controlled Release
  • 12.2. Smart Delivery
  • 12.3. Sustained Release
  • 12.4. Targeted Delivery

13. Drug & Gene Delivery Devices Market, by Therapeutic Area

  • 13.1. Cardiovascular
  • 13.2. Diabetes
  • 13.3. Infectious Diseases
  • 13.4. Oncology

14. Drug & Gene Delivery Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Drug & Gene Delivery Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Drug & Gene Delivery Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Becton Dickinson and Company
    • 17.3.2. West Pharmaceutical Services, Inc.
    • 17.3.3. Terumo Corporation
    • 17.3.4. Gerresheimer AG
    • 17.3.5. Baxter International Inc.
    • 17.3.6. Nipro Corporation
    • 17.3.7. Stevanato Group S.p.A.
    • 17.3.8. SHL Medical AG
    • 17.3.9. Ypsomed Holding AG
    • 17.3.10. Lonza Group AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG & GENE DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHN